LENALIDOMIDE CAPSULES LENALID 10

Lenalid is the Generic version of Revlimid manufactured by Natco which is manufactured by Natco Pharma Ltd. (INDIA)

Lenalid is used for the treatment of a certain type of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells) caused by an abnormal chromosome. Lenalid is also used for the treatment of anemia (a lack of red blood cells in the body) and along with dexamethasone for the treatment of multiple myeloma (a type of cancer of the bone marrow) who have received at least one prior therapy.

Lenalid, Lenalidomide Capsules 5 mg

Lenalidomide is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide has significantly improved overall survival in myeloma (which generally carries a poor prognosis), although toxicity remains an issue for users.

Lenalidomide Capsules 5 mg suppliers in India. Allevaire India New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for Lenalidomide Capsules 5 mg will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Multiple Myeloma: Lenalidomide in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.

Myelodysplastic Syndromes: Lenalidomide is indicated for the treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Mantle Cell Lymphoma: Lenalidomide is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

Medicine Name: Lenalid
Strength: 5mg, 10mg, 15mg, 25mg.
Dosage Form: Capsules in the bottle.
Retail Pack: 30’s.
Company Name: NATCO PHARMA LTD.

Available as (Form & Strength): Capsules in the bottle 5mg, 10mg, 15mg, 25mg